Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sagimet Biosciences Inc. Series A Common Stock (SGMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/07/2025: SGMT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 3.88% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 66.97M USD | Price to earnings Ratio - | 1Y Target Price 30.5 |
Price to earnings Ratio - | 1Y Target Price 30.5 | ||
Volume (30-day avg) 481333 | Beta - | 52 Weeks Range 1.73 - 7.38 | Updated Date 04/6/2025 |
52 Weeks Range 1.73 - 7.38 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.45 |
Earnings Date
Report Date 2025-03-12 | When - | Estimate -0.5853 | Actual -0.5 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.49% | Return on Equity (TTM) -36.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -84527637 | Price to Sales(TTM) 52.5 |
Enterprise Value -84527637 | Price to Sales(TTM) 52.5 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -1.93 | Shares Outstanding 30674900 | Shares Floating 19428281 |
Shares Outstanding 30674900 | Shares Floating 19428281 | ||
Percent Insiders 14.65 | Percent Institutions 57.75 |
Analyst Ratings
Rating 4.38 | Target Price 32.6 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sagimet Biosciences Inc. Series A Common Stock
Company Overview
History and Background
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic pathways in diseases such as nonalcoholic steatohepatitis (NASH) and certain cancers. Founded in 2006, they went public in 2023.
Core Business Areas
- NASH Drug Development: Sagimet's primary focus is developing Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of NASH.
- Oncology Drug Development: Developing FASN inhibitors for specific cancer indications.
Leadership and Structure
The leadership team includes key executives in drug development, clinical trials, and finance. They have a board of directors with expertise in biotech and pharmaceuticals.
Top Products and Market Share
Key Offerings
- Denifanstat: Denifanstat is Sagimet's lead product candidate for the treatment of NASH. Phase 2b clinical trial data is available. NASH market is still emerging. No specific market share at this time. Competitors include Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investments in research and development. The NASH market is large and growing, with significant unmet medical need.
Positioning
Sagimet is positioning itself as a leader in FASN inhibitor therapeutics for NASH and oncology. They are competing with larger, more established pharmaceutical companies.
Total Addressable Market (TAM)
NASH TAM is estimated to be $30-40 billion. Sagimet is positioning itself to capture a significant portion of this market with Denifanstat, pending successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel FASN inhibitor technology
- Promising Phase 2b clinical trial results for Denifanstat
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on a single lead product candidate
- Clinical trial risks and regulatory hurdles
Opportunities
- Potential for FDA approval of Denifanstat for NASH
- Expansion into other therapeutic areas with FASN inhibitors
- Strategic partnerships with larger pharmaceutical companies
Threats
- Competition from other NASH therapies in development
- Unsuccessful clinical trials
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- AKRO
Competitive Landscape
Sagimet faces competition from larger pharmaceutical companies with more resources and established products. Their competitive advantage lies in their novel FASN inhibitor technology and promising clinical trial results. None of the products are approved at this time, so all are zero
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and securing funding.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval for Denifanstat. Analyst estimates will be available as the company progresses.
Recent Initiatives: Recent initiatives include the completion of Phase 2b clinical trials and preparation for Phase 3 trials.
Summary
Sagimet Biosciences is a clinical-stage company with potential in the NASH market. The strength of the company is its novel drug Denifanstat and promising clinical results. The company's weaknesses include limited financial resources and the risks associated with drug development. Sagimet needs to closely monitor its cash burn rate and navigate regulatory hurdles to succeed.
Similar Companies
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
MDGL
Madrigal Pharmaceuticals Inc
MDGL
Madrigal Pharmaceuticals Inc
VKTX
Viking Therapeutics Inc
VKTX
Viking Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company filings, Investor presentations, Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sagimet Biosciences Inc. Series A Common Stock
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2023-07-14 | CEO, President & Director Mr. David A. Happel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.sagimet.com |
Full time employees 14 | Website https://www.sagimet.com | ||
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.